Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 26:11:1055131.
doi: 10.3389/fped.2023.1055131. eCollection 2023.

Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience

David Edward Youssef  1 , Stephanie S Handler  2 , Susan Marjorie Richards  1 , Catherine Anne Sheppard  1 , Jenna Smith  3 , Kathryn Tillman  2 , Matthew Pietrosanu  4 , Edward Kirkpatrick  2 , Angela Bates  1   5
Affiliations

Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience

David Edward Youssef et al. Front Pediatr. .

Abstract

Introduction: Phosphodiesterase type 5 (PDE5) inhibitors, with sildenafil the earliest among them, are widely used in the management of pediatric pulmonary arterial hypertension (PAH). Tadalafil is a PDE5 inhibitor with a long half life (16 h), stable pharmacokinetics and pharmacodynamics, and minimal adverse effects. However, the utility of tadalafil suspensions in this setting has not been widely explored due to a lack of clinical experience. We present a multicenter experience that details the safety and tolerability of a tadalafil suspension, either alone or in combination with another vasodilator, for the management of pediatric pulmonary hypertension (PH).

Methods and materials: This is a retrospective chart review of infants and children at Children's Wisconsin and the Stollery Children's Hospital enrolled in pediatric PH programs between December 2013 and April 2022 managed with a tadalafil suspension. Patients aged six years of age and under who were treated with a tadalafil suspension were included. Demographics, clinical information, echocardiographic and hemodynamic measurements, and laboratory data were collected before and six months after tadalafil initiation.

Results: Over the study period, 154 children with a median age of 1.0 (range 0.0-6.9) years were treated with tadalafil therapy. Of these, 39 (25.3%) were in group 1 (PAH), 79 (51.3%) were in group 3 (lung disease), and 33 (21.4%) were in group 5 (pulmonary hypertensive vascular disease). The median initial dose of tadalafil was 1.0 mg/kg once daily. Eleven (7.1%) patients in the cohort were established on tadalafil therapy de novo. The suspension formulation was necessary for 103 (66.9%) patients due to an inability to take enteral tablets and for 49 (31.8%) due to a need for feeding via gastric or jejunal tubes. We observed a statistically significant increase in tricuspid annular plane systolic excursion as well as significant decreases in right-ventricular systolic pressure and NT-proBNP. Tadalafil therapy was well tolerated over the six-month period: at six months, no adverse effects were reported aside from gastrointestinal disturbances by 2 (1.3%) patients.

Conclusion: Tadalafil, a long-acting PDE5 inhibitor, when administered in a suspension formulation, has a safe and tolerable adverse effect profile. Following six months of therapy, our cohort showed improvements in clinical parameters, echocardiographic measurements, and laboratory results. Patient compliance was good and adverse effects were rare, minor, and manageable with nonpharmacological means.

Keywords: adverse effect; echocardiography; hemodynamic; pulmonary vasodilator; safety; tolerability.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Histogram of age at tadalafil initiation.
Figure 2
Figure 2
WHO functional class before (n = 131) and six months after (n = 130) tadalafil initiation.
See this image and copyright information in PMC

References

    1. Hansmann G. Pulmonary hypertension in infants, children, and young adults. J Am Coll Cardiol. (2017) 69(20):2551–69. 10.1016/j.jacc.2017.03.575 - DOI - PubMed
    1. Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. (2019) 53(1):1801889. 10.1183/13993003.01889-2018 - DOI - PMC - PubMed
    1. Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol. (2012) 33(5):683–8. 10.1007/s00246-012-0180-4 - DOI - PMC - PubMed
    1. Ivy D, Bonnet D, Berger RMF, Meyer GMB, Beygani S, Li B, et al. Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study. Pulm Circ. (2021) 11(3):20458940211024955. 10.1177/20458940211024955 - DOI - PMC - PubMed
    1. Berman-Rosenzweig E, Arneson C, Klinger JR. Effects of dose and age on adverse events associated with tadalafil in the treatment of pulmonary arterial hypertension. Pulm Circ. (2014) 4(1):45–52. 10.1086/674901 - DOI - PMC - PubMed